When a DNA-repair pathway fails, developing brain cells lose their mitochondria too — in lab-grown human cells

Edited by Samael A. Tejada, Founder & Editor-in-Chief

A disorder famous for failing bone marrow also quietly damages the developing brain, and nobody could say why. This study follows the damage to an unlikely culprit — a surge of formaldehyde the cells make themselves — and shows mitochondria among the casualties when the repair crew that should clear it is missing.

What did the study actually find?

Fanconi anemia (FA) is a congenital DNA-repair disorder classically marked by bone-marrow failure, yet patients also show congenital malformations and progressive neurodegeneration that lacked a mechanism. Working in human cellular models, Shi and colleagues found that loss of the FA pathway selectively compromised neuroectodermal lineage progression — the developmental path that produces neurons and glia. Cells lacking FANCL showed impaired neuronal morphology, defective expression of neuronal and oligodendroglial markers, mitochondrial dysfunction, and defective electrophysiology: the cells looked wrong, powered themselves wrong, and fired wrong.

Where does formaldehyde come in?

The mechanism is endogenous — the poison is homemade. Transcriptional reprogramming during neural differentiation triggers a metabolic surge of formaldehyde, a normal metabolic byproduct. In healthy cells the FA pathway and detoxifying enzymes handle the resulting DNA-protein crosslinks (DPCs). In FANCL-deficient cells the crosslinks accumulated and apoptosis followed. The decisive test: restoring either FANCL or ADH5, the formaldehyde-detoxifying enzyme, effectively rescued the defects. The team also found that conditioned media from the deficient cultures induced a reactive astrogliosis-like response in recipient cells — a non-cell-autonomous, pro-inflammatory component, meaning the harm radiates outward to neighboring cells that do not carry the defect.

What does this mean for patients — and for mitochondria science?

Boundaries first: these are human cellular models, not patients; no person received FANCL restoration, ADH5 support, or any intervention, and the study tests no treatment. What it changes is the map. It establishes the FA pathway as a safeguard of neurodevelopment, puts mitochondrial dysfunction inside the causal chain of a DNA-repair disorder's brain effects rather than downstream as a vague association, and names a druggable-looking node — formaldehyde detoxification — for future work. Whether boosting ADH5 or limiting formaldehyde helps a human brain is entirely untested, and this page does not claim otherwise.

Where the evidence stands

• Established: Fanconi anemia is a congenital DNA-repair disorder classically characterized by bone-marrow failure; formaldehyde is an endogenous metabolite that creates DNA-protein crosslinks; and mitochondrial dysfunction is a recognized feature of several neurodegenerative conditions.
• Preliminary: In human cellular models (Cell Death & Disease, Nov 2, 2026; DOI 10.1038/s41419-026-09388-4), FANCL loss impaired neuronal morphology and markers, caused mitochondrial dysfunction and defective electrophysiology, and drove formaldehyde-linked crosslink accumulation and apoptosis — all rescued by restoring FANCL or ADH5, with a pro-inflammatory effect on recipient cells from conditioned media.
• Absent: Patient intervention data of any kind, in-vivo confirmation of the formaldehyde mechanism, and any tested therapy targeting ADH5 or formaldehyde in Fanconi anemia.